Vectura foresees important catalysts in second half

13 August 2013

Shares of UK-based developer of inhaled therapies Vectura (LSE: VEC) rose 1.6% to 96 pence in mid-morning trading today, after the company said it is expecting a strong second half and a number of catalysts, in an interim management statement.

Its pipeline update included news on QVA149/Ultibro Breezhaler (indacaterol maleate/glycopyrronium bromide) which received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) last month for patients with COPD for its partner Swiss drug major Novartis (NOVN: VX) ( The Pharma Letter July 29). An application has also been submitted to the Japanese Ministry of Health, Labor and Welfare in November 2012 and a US New Drug Application is expected to be filed at the end of 2014.

Clinical developments

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK